ProImmune Launches B Cell ELISpot Assay Service

ProImmune Ltd. has launched the B cell ELISpot assay as a service. The B cell ELISpot assay is central to the characterization of adaptive immune responses to infection, immune modulators, vaccines and therapeutic agents.

Used to quantify the number of memory B cells that can be re-stimulated to produce antibody against a specific antigen, B cell ELISpot enables the activity of antibody-secreting memory B cells to be characterized at a cellular level.

This gives a more detailed reading of immune responses in contrast to an ELISA-type assay, which measures total levels of secreted antibodies in a sample.

Dr Nikolai Schwabe, CEO of ProImmune said: “The B cell ELISpot is a highly valuable assay offering a superior method for characterization of memory antibody responses, the investigation of which forms a mainstay of evaluating functional immune responses. Although the assay is technically challenging, requiring extensive experience, when performed correctly it is very robust and is therefore very well suited to be run as a core facility service.”

To read further information about the B Cell ELISpot Assay Service, please visit http://bit.ly/HPHW4R.